Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced successful outcomes from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study met its primary objective by demonstrating biological efficacy, with SGX945 showing a 40% improvement in the primary ulcer endpoint compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study. Notably, these results were achieved despite the treatment period being limited to four weeks.
The open-label trial involved eight patients, seven of whom reported significant reductions in ulcer duration, number, and pain. These benefits persisted throughout the follow-up period, with no treatment-related adverse events reported. Christopher J. Schaber, CEO of Soligenix, highlighted the potential of SGX945, including plans for reformulation for home-based subcutaneous administration, as part of a broader strategy to tackle unmet needs in Behçet’s Disease and other innate immune-related inflammatory conditions.
This development is a critical step forward for Soligenix, which is also advancing other innovative therapies in its pipeline. The company's Specialized BioTherapeutics segment is focusing on HyBryte(TM) for cutaneous T-cell lymphoma and expanding synthetic hypericin into psoriasis treatment. Additionally, its Public Health Solutions segment is developing vaccines for ricin toxin, filoviruses, and COVID-19, leveraging its proprietary ThermoVax(R) technology.
The positive results from the SGX945 study not only underscore Soligenix's commitment to addressing rare and challenging diseases but also highlight the potential of dusquetide as a transformative treatment for Behçet’s Disease and possibly other inflammatory conditions. For more details on the study, visit https://ibn.fm/FqcXf.